Australia markets closed

Precipio, Inc. (PRPO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0800+0.0200 (+1.89%)
At close: 04:00PM EDT
1.1200 +0.04 (+3.70%)
After hours: 06:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0600
Bid0.0000 x 1000
Ask0.0000 x 1300
Day's range1.0600 - 1.0950
52-week range0.9100 - 4.1700
Avg. volume253,109
Market cap24.525M
Beta (5Y monthly)2.27
PE ratio (TTM)N/A
EPS (TTM)-0.5230
Earnings date22 Aug 2022 - 26 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Precipio requests that all Stockholders that have not yet voted, proceed to cast their vote

    Meeting Adjourned, new meeting set for July 5th at 10am EDTNEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced today that the Company’s 2022 Annual Meeting of Stockholders was adjourned due to the fact that the percentage of stockholders participating in the proxy vote totaled approximately 49%, thereby not reaching the quorum of 50% required to conduct business and approve the measures. The meeting is rescheduled for July 5th

  • GlobeNewswire

    Keith Meadors Joins Precipio to Lead its Products Division

    Seasoned, experienced industry executive with a track record of managing 9-figure revenue sales organizationsNEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and market share. Keith brings over 30 years of executive experience in various healthcare organizations, including his recen

  • GlobeNewswire

    Precipio Receives CE-IVD Certification to Market Multiple HemeScreen® Panels in Europe

    This Regulatory Approval Opens the Company’s Reach to the European MarketNEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union. The approval was provided by the Medicines & Healthcare Products Regulatory Agency. The CE-IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification allows Precipio to market t